Drug Trial Radar · NCT02681055
Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
Last checked: Nov 19, 2026Latest source record: Mar 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Mar 2016
Primary completion
May 30, 2018
Study completion Oct 1, 2019
Sponsor
- Lead sponsor
- MediciNovaIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in non-alcoholic steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) subjects with hypertriglyceridemia.
Conditions
- Non-alcoholic Steatohepatitis
- Hypertriglyceridemia
- Non-alcoholic Fatty Liver Disease
- Hypercholesterolemia
Interventions
MN-001Drug
MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline at 12 Weeks of MN-001 Treatment on Cholesterol Efflux CapacityTime frame: Baseline, 12 weeks
- Mean Change From Baseline to Week 8 on Triglyceride Levels After 8 Weeks MN-001 TreatmentTime frame: 8 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Southern California Research Center
Coronado, California
Scripps Research
La Jolla, California
Harborview Medical Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.